CDMOS as Strategic Enablers for Device Industrialisation
Key takeaways
- Successfully getting a medical device to market requires an integrated strategy for design and manufacture, which manages risk at each stage of the development process.
- GLOBAL CAPACITY AND FLEXIBLE MANUFACTURING
- One of the most critical assets in today’s medical device landscape is manufacturing capacity and a flexible global footprint.
CDMOS as Strategic Enablers for Device Industrialisation Staff Writer Thu, May 21, 2026 at 8:55 PM GMT+7 6 min read Global challenges such as navigating an increasingly complicated regulatory landscape, an overall global lack of manufacturing capacities, and high levels of geopolitical uncertainty only add to the challenge. Successfully getting a medical device to market requires an integrated strategy for design and manufacture, which manages risk at each stage of the development process. In this context, the right CDMO is more than a vendor – it should and can be a strategic enabler.
GLOBAL CAPACITY AND FLEXIBLE MANUFACTURING
One of the most critical assets in today’s medical device landscape is manufacturing capacity and a flexible global footprint. The surge in demand for GLP1s has led to a massive demand for manufacturing capacity from big pharma companies for the devices that deliver them. This in turn has created a shortage of capacity for other medical device companies. In particular, the need to produce smaller batches of devices for clinical trials is becoming increasingly difficult as the capabilities required in terms of agility often differ from those for high-volume production.